Key statistics
On Wednesday, Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (6990:HKG.HZ) closed at 348.00, 55.91% above the 52 week low of 223.20 set on Mar 04, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 350.00 |
|---|---|
| High | 355.40 |
| Low | 339.60 |
| Bid | 348.00 |
| Offer | 348.20 |
| Previous close | 351.40 |
| Average volume | 426.72k |
|---|---|
| Shares outstanding | 233.19m |
| Free float | 112.76m |
| P/E (TTM) | -- |
| Market cap | 81.94bn HKD |
| EPS (TTM) | -3.66 HKD |
Data delayed at least 15 minutes, as of Mar 04 2026 08:08 GMT.
More ▼
Press releases
- Kelun-Biotech Announces Fourth Indication for Sacituzumab Tirumotecan (sac-TMT) Approved by NMPA in HR+/HER2- Breast Cancer
- Kelun-Biotech Showcases Innovative Achievements and Future Development Strategy at the 44th Annual JPM Healthcare Conference
- Kelun-Biotech to Attend the 44th J.P. Morgan Healthcare Conference, Sharing Its Business Progresses and Innovation Strategies
- Kelun-Biotech Receives Investigational New Drug Approval for ITGB6-Targeted ADC SKB105 from the NMPA
- Kelun-Biotech Announces Breakthrough Therapy Designation Granted in China for Sacituzumab Tirumotecan (sac-TMT) in Combination with Immunotherapy Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC
More ▼
